Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms/Experiment 1
Subjects
- Location of subjects
- Thailand
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Vaginal fluid Vaginal discharge,Vaginal secretion,Vaginal fluid,vaginal fluid
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Breast carcinoma breast cancer,breast cancer, NOS,breast carcinoma,cancer of breast,cancer of the breast,cancer, breast,carcinoma of breast,carcinoma of the breast,mammary carcinoma,Breast carcinoma
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Non-vulvovaginal symptoms (control)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Vulvovaginal symptoms
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Participants in the vaginal symptom group
- Group 0 sample size Number of subjects in the control (unexposed) group
- 20
- Group 1 sample size Number of subjects in the case (exposed) group
- 20
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Within 7 days
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2.0
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Source: FIG 3 (A)
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms. (A) Taxa with a significant difference in both groups were detected by LEfSe analysis with a linear discriminant analysis (LDA)
Abundance in Group 1: increased abundance in Vulvovaginal symptoms
Revision editor(s): Rahila
Signature 2
Source: FIG 3 (A)
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms. (A) Taxa with a significant difference in both groups were detected by LEfSe analysis with a linear discriminant analysis (LDA)
Abundance in Group 1: decreased abundance in Vulvovaginal symptoms
| NCBI | Quality Control | Links |
|---|---|---|
| Parvimonas micra |
Revision editor(s): Rahila
